LYS006

LYS006 is a novel, highly potent and selective small molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the final and rate-limiting enzyme in the biosynthesis of pro-inflammatory leukotriene B4 (LTB4). By inhibiting LTA4H, LYS006 suppresses the production of LTB4, a key mediator in neutrophil-driven inflammatory diseases. The drug has demonstrated strong pharmacodynamic effects with high selectivity and long-lasting inhibition of its target at low exposures. It is being developed for several neutrophil-driven inflammatory conditions including hidradenitis suppurativa, inflammatory acne, ulcerative colitis, and non-alcoholic steatohepatitis (NASH). Clinical studies have shown that it is well-tolerated with no dose-limiting toxicity up to the highest doses tested[1][2][3][4]. Developed by Novartis.